Skip to main content

Zymeworks Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

ZYME$31.46+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Condensed Consolidated Statement of Changes in Stockholders’ Equity

(Expressed in thousands of U.S. dollars except share data)

Preferred stock · Exchangeable shares · Common stock · Accumulateddeficit · Accumulatedothercomprehensive loss · Additionalpaid-incapital · Totalstockholders’equity
Shares · Amount · Shares · Amount · Shares · Amount
Balance at January 1, 20251$—570,637$8,18868,964,319$1,015,618$(830,335)$(6,952)$152,249$338,768
Issuance of common stock on exercise of options————84,8631,208——(437)771
Issuance of common stock through employee stock purchase plan————74,274724———724
Issuance of common stock upon vesting of restricted stock units (“RSUs”)————460,6204,390——(4,390)—
Issuance of common stock for retracted exchangeable shares (note 8a)——(735)(10)73510————
Stock-based compensation————————6,7946,794
Net loss——————(22,636)——(22,636)
Other comprehensive income———————546—546
Balance at March 31, 20251$—569,902$8,17869,584,811$1,021,950$(852,971)$(6,406)$154,216$324,967
Issuance of common stock on exercise of options————174,8562,267——(882)1,385
Issuance of common stock upon exercise of pre-funded warrants (note 8c)————5,086,48049,862——(49,862)—
Stock-based compensation————————5,7715,771
Net income——————2,317——2,317
Other comprehensive income———————66—66
Balance at June 30, 20251$—569,902$8,17874,846,147$1,074,079$(850,654)$(6,340)$109,243$334,506
Preferred stock · Exchangeable shares · Common stock · Accumulateddeficit · Accumulatedothercomprehensiveloss · Additionalpaid-incapital · Totalstockholders’equity
Shares · Amount · Shares · Amount · Shares · Amount
Balance at January 1, 20241$—651,219$9,34570,115,997$997,227$(677,437)$(6,603)$142,274$464,806
Issuance of common stock on exercise of options————203,5182,581——(626)1,955
Issuance of common stock through employee stock purchase plan————52,905577———577
Issuance of common stock upon vesting of RSUs————224,1041,939——(1,939)—
Issuance of common stock for retracted exchangeable shares (note 8a)——(80,582)(1,157)80,5821,157————
Stock-based compensation————————3,4353,435
Net loss——————(31,653)——(31,653)
Other comprehensive loss———————(1,121)—(1,121)
Balance at March 31, 20241$—570,637$8,18870,677,106$1,003,481$(709,090)$(7,724)$143,144$437,999
Issuance of common stock on exercise of options————154,4391,829——(692)1,137
Stock-based compensation————————4,8914,891
Net loss——————(37,686)——(37,686)
Other comprehensive loss———————(180)—(180)
Balance at June 30, 20241$—570,637$8,18870,831,545$1,005,310$(746,776)$(7,904)$147,343$406,161

The accompanying notes are an integral part of these financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.